BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34115544)

  • 21. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential Impact of
    O'Donohue T; Gulati N; Mauguen A; Kushner BH; Shukla N; Rodriguez-Sanchez MI; Bouvier N; Roberts S; Basu E; Cheung NK; Modak S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
    Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
    Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.
    Guimier A; Ferrand S; Pierron G; Couturier J; Janoueix-Lerosey I; Combaret V; Mosseri V; Thebaud E; Gambart M; Plantaz D; Marabelle A; Coze C; Rialland X; Fasola S; Lapouble E; Fréneaux P; Peuchmaur M; Michon J; Delattre O; Schleiermacher G
    PLoS One; 2014; 9(7):e101990. PubMed ID: 25013904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic roles of and correlation between
    Chang HH; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Hsu WM; Jeng YM; Jou ST
    J Clin Pathol; 2020 Mar; 73(3):154-161. PubMed ID: 31542727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.
    Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ;
    Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
    Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
    Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
    Ladenstein R; Lambert B; Pötschger U; Castellani MR; Lewington V; Bar-Sever Z; Oudoux A; Śliwińska A; Taborska K; Biassoni L; Yanik GA; Naranjo A; Parisi MT; Shulkin BL; Nadel H; Gelfand MJ; Matthay KK; Park JR; Kreissman SG; Valteau-Couanet D; Boubaker A
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):292-305. PubMed ID: 28940046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
    Yi B; Yang J; Wang L
    Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
    Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
    Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
    Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
    J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.
    Carén H; Abel F; Kogner P; Martinsson T
    Biochem J; 2008 Dec; 416(2):153-9. PubMed ID: 18990089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two siblings with familial neuroblastoma with distinct clinical phenotypes harboring an ALK germline mutation.
    Kudo K; Ueno H; Sato T; Kubo K; Kanezaki R; Kobayashi A; Kamio T; Sasaki S; Terui K; Kurose A; Yoshida K; Shiozawa Y; Toki T; Ogawa S; Ito E
    Genes Chromosomes Cancer; 2018 Dec; 57(12):665-669. PubMed ID: 30350464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
    Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
    PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
    Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
    Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.
    Somasundaram DB; Aravindan S; Gupta N; Yu Z; Baker A; Aravindan N
    World J Pediatr; 2022 Apr; 18(4):285-293. PubMed ID: 35132576
    [No Abstract]   [Full Text] [Related]  

  • 40. Generation of conditional ALK F1174L mutant mouse models for the study of neuroblastoma pathogenesis.
    Ono S; Saito T; Terui K; Yoshida H; Enomoto H
    Genesis; 2019 Oct; 57(10):e23323. PubMed ID: 31218818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.